Active, not recruitingPhase 3NCT04967521
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
Studying Dedifferentiated liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Principal Investigator
- Mark Dickson, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Abemaciclib(drug)
- Enrollment
- 108 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (9)
- University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Duke University, Durham, North Carolina, United States
- Oregon Health & Science University, Portland, Oregon, United States
- University of Washington, Seattle, Washington, United States
Collaborators
Eli Lilly and Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04967521 on ClinicalTrials.govOther trials for Dedifferentiated liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06498648Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06422806Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06389799A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)Lund University Hospital
- RECRUITINGPHASE1NCT05711615Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT05694871Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated LiposarcomaAlliance for Clinical Trials in Oncology
- ACTIVE NOT RECRUITINGPHASE2NCT05886634A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated LiposarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT05607095A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated LiposarcomaMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT04420975Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaJonsson Comprehensive Cancer Center